Enveda
What they do & why Kinnevik is invested
Enveda is revolutionizing drug discovery by tapping into the vast potential of life’s chemical diversity. Using its AI-driven search engine, the company decodes and maps the complex chemistry found in living systems, unlocking an untapped dark chemical space and discovering novel drug candidates.
Founded by molecular biologist Viswa Colluru – formerly of Recursion, another Kinnevik company (glance to your right) – Enveda was built on the belief that nature holds answers to many diseases. Though some of the most successful drugs in human history came from plants, nature-inspired drug discovery declined because of the slow, inefficient, and difficult process of interpreting plant chemistry. Enveda overcomes this through its proprietary platform built around mass spectrometry, machine learning, and advanced robotics.
Enveda’s platform has generated 16 preclinical programs in just five years, over 12 development candidates, four assets in IND (Investigational New Drug) enabling studies, and one candidate that just entered a Phase 1b trial following successful Phase 1a trials. Over the next 1-2 years, Enveda is dedicated to advancing key programs in atopic dermatitis, asthma, obesity, and liver diseases to critical value-inflection milestones, partnering select programs to unlock near-term value through strategic business development.
Kinnevik is attracted by Enveda’s innovative approach to drug discovery and its potential to redefine health. By combining novel AI with deep scientific expertise, Enveda addresses longstanding challenges in uncovering effective treatments, positioning itself as a highly promising player in the sector.
Key information
- Clinical-stage biotech company pioneering small molecule drug discovery inspired from life’s chemistry
- Leverages mass spectrometry, robotics, and advanced machine-learning techniques to map life’s chemistry and uncover novel therapeutics - 4x faster and at 1/10 of the cost compared to the industry average
- Focused on advancing novel drugs to critical value-inflection milestones through internal development, retaining optionality of partnering out selective programs
News in the quarter
- Raised USD 150m Series D funding, reaching unicorn status in five years from seed. The new funds will be used to accelerate the company’s deep clinical-stage pipeline of novel medicines, addressing diseases that affect over 100 million patients worldwide
- Dosed first patient in a Phase 1b clinical trial for the company’s lead candidate targeting atopic dermatitis (eczema)
- Appointed Dr. Mikael Dolsten, former Pfizer Chief Scientific Officer and current Novo Nordisk Board Member, to its Board of Directors
